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A B S T R A C T
The pathogenesis of colorectal cancer (CRC) involves different mechanisms, such as genomic and microsatellite
instabilities. Recently, a contribution of the base excision repair (BER) pathway in CRC pathology has been
emerged. In this context, the involvement of APE1 in the BER pathway and in the transcriptional regulation of
genes implicated in tumor progression strongly correlates with chemoresistance in CRC and in more aggressive
cancers. In addition, the APE1 interactome is emerging as an important player in tumor progression, as de-
monstrated by its interaction with Nucleophosmin (NPM1). For these reasons, APE1 is becoming a promising
target in cancer therapy and a powerful prognostic and predictive factor in several cancer types. Thus, specific
APE1 inhibitors have been developed targeting: i) the endonuclease activity; ii) the redox function and iii) the
APE1-NPM1 interaction. Furthermore, mutated p53 is a common feature of advanced CRC. The relationship
between APE1 inhibition and p53 is still completely unknown. Here, we demonstrated that the inhibition of the
endonuclease activity of APE1 triggers p53-mediated effects on cell metabolism in HCT-116 colon cancer cell
line. In particular, the inhibition of the endonuclease activity, but not of the redox function or of the interaction
with NPM1, promotes p53 activation in parallel to sensitization of p53-expressing HCT-116 cell line to genotoxic
treatment. Moreover, the endonuclease inhibitor affects mitochondrial activity in a p53-dependent manner.
Finally, we demonstrated that 3D organoids derived from CRC patients are susceptible to APE1-endonuclease
inhibition in a p53-status correlated manner, recapitulating data obtained with HCT-116 isogenic cell lines.
These findings suggest the importance of further studies aimed at testing the possibility to target the en-
donuclease activity of APE1 in CRC.
1. Introduction
Colorectal cancer (CRC) is considered the third most common
cancer and the fourth most common cause of cancer-related death
worldwide [1]. CRC is a multistep process involving a series of histo-
morphological and genetic changes, that accumulate over time in the
epithelial layer of the intestinal tract. Interestingly, genetic and epige-
netic modifications lead to the activation of oncogenes and/or the in-
activation of tumor suppressor genes, as formulated by Volgestein and
Fearon [2,3]. Both genetic and environmental factors are essential in
the etiology of the disease. About 70% of CRC patients suffer from a
sporadic form, whereas 10–30% present a familial predisposition and
only 5–7% exhibit an inherited trait [4]. However, the most common,
often overlapping, mechanisms involved in the pathogenesis of CRC are
represented by the chromosome and microsatellite instabilities, the
CpG island methylator phenotype and the deletion of the long arm of
chromosome 18 [1,5]. In the landscape of chromosome instability, the
most common mutations occur in specific tumor suppressor genes (e.g.
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APC, PTEN, SMAD4, TGFBR2, TP53) or oncogenes (e.g. BRAF, KRAS,
PIK3CA). Recently, the involvement of DNA repair genes has been de-
monstrated to be associated with the pathogenesis of CRC [6–8]. In
particular, both endogenous (e.g. metabolic activity of the cells) and
exogenous factors (e.g. food intake) are involved in DNA damage,
which requires the activation of the DNA repair mechanisms. In parti-
cular, the base excision repair (BER) pathway is involved in repairing
DNA chemical modifications, such as deamination, oxidation, and al-
kylation [9]. Interestingly, BER has been found altered in CRC, as de-
monstrated by the presence of single nucleotide polymorphisms (SNPs)
in several BER genes including DNA glycosylases, apurinic/apyr-
imidinic endonuclease 1 (APE1) and DNA Polymerase β (Pol β) [10]. In
BER, APE1 cleaves the DNA phosphodiester backbone on the 5′ side of
an abasic apurinic/apyrimidinic (AP) site, previously produced by the
action of damage-specific glycosylases, generating a nick in the DNA
and leaving 3′ hydroxyl and 5′ dRP free termini, which are processed
and replaced by a correct nucleotide by Pol β [11]. Recent molecular
snapshots of the endonuclease-reaction clearly defined the APE1 cata-
lytic mechanism of action [12]. The catalytic site of the enzymes in-
volves a Mg2+ ion coordinated by Asp70, Glu96 and a water molecule
in contact with non-bridging oxygen of the phosphate. Additionally, the
nucleophilic water is in position for in-line attack of the phosphorus
atom and is coordinated by Asn212 and Asp210. APE1 is also endowed
of an exonuclease activity through the removal of 3’ end groups of a
mismatched or DNA damaged bases to generate substrates that are
processed by the downstream repair enzymes [13]. Recently, we de-
monstrated that APE1 plays an important role in the recognition and
processing of ribose monophosphate AP sites and oxidized ribonu-
cleotides embedded in DNA through a classical AP endonuclease ac-
tivity and a nucleotide incision repair (NIR) activity, respectively [14].
As widely described, APE1 is implicated in cancer gene expression
regulation due to its role as a redox co-activator of several transcription
factors, such as Egr-1, NF-κB, p53, STAT3, HIF-1α, CREB, AP-1, and
Pax-5/8 [15]. APE1 is considered as a unique nuclear redox-signaling
factor bearing seven Cys residues. Three of the Cys residues, C65, C93,
and C99, are essential for its redox activity, that involves a redox cycle
through the potential formation of intermolecular disulfide bonds with
the protein target [16–20]. While C65 acts as the nucleophilic cysteine,
C93 and C99 likely play roles in resolving disulfide bonds that are
formed in APE1 upon oxidation. Structural studies demonstrated that
APE1 exists in both native and partially unfolded conformations, con-
trolled by Thioredoxin (TRX) [16], in which the partially unfolded state
of APE1 represents the redox active intermediate of the enzyme.
Recently, it has been demonstrated that APE1 is not only involved in
DNA repair mechanisms and transcriptional regulation, but also in
miRNA metabolism [21]. Furthermore, the interaction between APE1
and Nucleophosmin (NPM1) is essential for the subcellular localization
of APE1 modulating its endonuclease activity [22]. Interestingly, this
interaction was found altered in ovarian cancer promoting tumor ag-
gressiveness and resistance. Finally, it has been demonstrated that in
the majority of cases, there is a positive correlation between upregu-
lated expression of APE1 and the development of several tumors, such
as: colon [23,24], breast [25], hepatic [26], prostate [27], pancreatic
[28], ovarian [29], lung cancers [30], leukemias [31] and many others
[32]. Furthermore, APE1 overexpression is associated with the onset of
chemoresistance phenomena [22]. For these reasons, APE1 is con-
sidered a promising prognostic and predictive biomarker [33] and
several strategies have been developed to inhibit its functions in cancer
cells [34], leading to the development of ongoing clinical trials.
In recent years, a great effort has been put in the development of
specific inhibitors targeting the different functions of APE1, i.e.
Compound #3, APX2009, Spiclomazine, Fiduxosin and SB206553.
Compound #3 blocks the endonuclease activity of APE1 acting as a
competitive inhibitor by binding the active site of the enzyme and
consequently leading to a decrease of APE1-DNA complex formation in
a dose-dependent manner [35]. The inhibition promotes, in turn, an
increase of the unrepaired AP sites accumulation in genomic DNA, that,
in combination with an alkylating agent treatment, such as methyl
methanesulfonate (MMS), induces high levels of cellular death [36,37].
APX2009, an APE1 specific redox inhibitor, is the second generation
molecules of the drug APX3330, previously named E3330 [38].
APX3330 inhibits the activator function of APE1 on different tran-
scription factors such as NF-κB, AP-1, HIF-1 and STAT3 [18,39,40]. In
particular, APX3330 increases disulfide bonds involving C65 and/or
C93 residues in APE1, impairing its redox activity [41]. APX3330 re-
cently completed cancer phase I clinical trials with demonstrated
safety, response and APE1 target engagement [42,43]. Finally, Spiclo-
mazine, Fiduxosin, and SB206553 molecules inhibit the interaction of
APE1 with NPM1, a protein involved in rRNA biogenesis, by directly
binding to the N-terminal domain of APE1. We demonstrated that these
inhibitors alter the localization and the endonuclease activity of APE1,
but not the rRNA maturation [22] and induce apoptosis in different
tumor cell lines [22,44]. To our knowledge, only one study investigated
the ability of the APE1-redox inhibitor (APX3330) to affect colon cancer
stem cells (CCSCs) growth in vitro and to enhance the effect of the
chemotherapeutic agent 5-Fluorouracil (5-FU) in CCSCs xenograft mice
[23]. Thus, the importance of exploring the effect of different APE1
inhibitors in CRC models is apparent. Here, we used the well-known
HCT-116 colon cancer cell model, to explore the relevance of p53 upon
APE1 inhibition, and extended our findings using a 3D organoid cul-
tures model derived from CRC affected patients.
Due to the intricate mechanisms that characterize the CRC etiology,
research has focused on personalized precision medicine of CRC. The
generation of patient-derived 3D tumor organoids will greatly enhance
our understanding of the disease complexity and the heterogeneity in
order to develop patient-specific therapies [45]. Organoids have a
special property to mirror the key-features of the original patient’s
tissue [46], representing an ideal tool to develop patient-specific
therapies by performing drug screenings.
Similarly to APE1, the well-known tumor suppressor gene TP53 has
been found altered in most tumors [47]. The wild-type p53 protein is a
transcription factor involving in cell cycle arrest, senescence and
apoptosis, besides being a key player in the DNA Damage Response
(DDR) to single-strand breaks (SSBs) and double-strand break (DSBs)
accumulation. Among all the mutated genes promoting CRC, p53 has an
important role [48]. Indeed, loss of p53 function stimulates the devel-
opment of the late stage of CRC and is associated with poor prognosis
[49]. p53 plays a role not only as a modulator of the cell cycle to
guarantee genome stability, but it is also directly involved in the acti-
vation of proteins that are associated with DNA repair processes [50].
In particular, it has been demonstrated that p53 prevents genomic in-
stability through a BER gene expression regulation [51]. Importantly,
p53 regulates DNA glycosylases (OGG1 and MUTYH) [52,53], APE1
[54,55], Pol β [56] expression and acts as a transcriptional repressor of
DNA polymerase δ [57]. However, it is unknown whether p53 is part of
DDR starting from AP sites accumulation as a consequence of APE1
inactivation or inhibition. The present study was aimed at addressing
this issue. Furthermore, data on whether APE1 inhibitors may affect cell
viability of colon cancer cells through p53-induced cell response are the
focus of the work presented here.
2. Materials and methods
2.1. Cell cultures
HCT-116 p53+/+ and HCT-116 p53−/− (ATCC®) cells were grown
in Dulbecco’s modified Eagle’s medium (EuroClone, Milan, Italy) sup-
plemented with 10% fetal bovine serum (EuroClone). CH12 F3+/+/Δ
and CH12 F3Δ/Δ/Δ cells were grown in RPMI 1640 (EuroClone) sup-
plemented with 10% fetal bovine serum (EuroClone), 1X non Essential
Amino Acids (EuroClone), 1 mM Sodium Pyruvate (EuroClone), 25mM
HEPES (EuroClone) and 50 μM β-mercaptoethanol (Promega, Madison,
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WI, USA). OCI-AML2 cells were grown in α-MEM (Invitrogen, Carlsbad,
CA, USA) supplemented with 20% fetal bovine serum (EuroClone).
HCC70 cells were grown in RPMI 1640 (EuroClone) supplemented with
10% fetal bovine serum (EuroClone). All culturing media were also
supplemented with 2mM GlutaMAX (EuroClone), 100 U/ml penicillin
and 10 μg/ml streptomycin (EuroClone).
2.2. Human tissues
Colonic tissues were obtained upon surgical resection from the
University Hospital Santa Maria della Misericordia of Udine. All pa-
tients were diagnosed with colorectal cancer. This study was approved
by the ethical committee of University Hospital Santa Maria della
Misericordia of Udine (CEUR-2017-PR-048-UNIUD) and all samples
were obtained prior to informed consent.
2.3. Organoid culture
The generation of patient-derived tumor organoids was performed
as described by [58] with some modifications. Tumor intestinal tissue
was washed with ice-cold PBS supplemented with 100 U/ml penicillin
and 10 μg/ml streptomycin (EuroClone) several times. Tumor tissue
was homogenized with scissors and then digested with 0.26 U/ml
Liberase (Sigma-Aldrich, St. Louis, MO, USA) in basal medium, com-
posed of Advanced DMEM/F12 (Life Technologies, Carlsbad, CA, USA)
supplemented with 2mM Glutamax (Life Technologies), 10mM HEPES
(Life Technologies), 100 U/ml penicillin and 10 μg/ml streptomycin
(EuroClone) complemented with 100 μg/ml Primocin (InvivoGen, San
Diego, CA, USA) and 10 μM Y-27632 (Abcam, Cambridge, UK) for 1 h at
37 °C shaking at 250 rpm. The resulting fraction was passed through a
100-mm cell strainer. The filtered solution was centrifuged at 1200 rpm
for 5min at 4 °C. The cell pellet was resuspended with Red Blood Cell
(RBC) Lysis Buffer (BioLegend, San Diego, CA, USA) and incubated for
10min at room temperature (RT) in the dark. RBC buffer was neu-
tralized adding basal medium complemented with 10% fetal bovine
serum (BioWest, Nuaillé, France). The resulting solution was cen-
trifuged at 1200 rpm for 5min at 4 °C and the cell pellet was re-
suspended with 3ml of basal medium. Cells were counted with a Burker
chamber and 200,000 cells/10 μl were mixed with 20 μl of Matrigel and
30 μl drop was plated in a single well of 24-well. After polymerization
of Matrigel (Corning®, Corning, NY, USA) for 10–15min at 37 °C, 500 μl
of culture medium was added. Tumor organoids were cultured in basal
medium containing 1X B27 (Life Technologies), 1.15mM N-acet-
ylcysteine (Sigma-Aldrich), 10mM Nicotinamide (Sigma-Aldrich),
10 nM Gastrin I (Tocris Bioscience, Bristol, UK), 10 nM Prostaglandin E2
(Sigma-Aldrich), 500 nM A83-01 (R&D System, Minneapolis, MN, USA),
50 ng/ml mEGF (PeproTech, London, UK), 3 μM SB202190 (Sigma-
Aldrich), 10% Noggin Conditioned Medium, 20% R-Spondin1 Condi-
tioned Medium, 10 μM Y-27632 (Abcam) and 100 μg/ml Primocin
(InvivoGen). The medium was refreshed every two/three days. Tumour
organoids were passaged 1:4 every one/two weeks.
2.4. Treatments
Compound #3 was kindly provided by the National Center for
Advancing Translational Sciences. APX2009 was kindly provided by
Professor Mark R. Kelley (Indiana University, School of Medicine).
Fiduxosin, SB206553, Spiclomazine were purchased as previously de-
scribed [22]. All compounds were solved in dimethyl sulfoxide (DMSO).
IC50 values were calculated using Combenefit 2.021 Software.
2.5. RNA interference
One day before transfection, cells were seeded in 60-mm plates at a
density of 600,000 cells per plate. Cells were then transiently trans-
fected with 100 pmol siRNA APE1 5ʹ-UACUCCAGUCGUACCAGACCU-3ʹ
or the scramble control siRNA 5ʹ-CCAUGAGGUCAUGGUCUGdTdT-3ʹ
(Dharmacon, Lafayette, CO, USA) using DharmaFECT reagent
(Dharmacon). After 72 h upon transfection, cells were collected and
whole cell extracts were prepared.
2.6. Preparation of the cell extracts and protein quantification
For the preparation of whole cell lysates, 200,000 HCT-116 cells
were plated on 6-well plates and, the following day, cells were treated
with Compound #3 or APX2009. After 48 h cells were collected by
trypsinization and centrifuged at 250 x g for 5min. The supernatant was
removed, and the pellet was washed once with PBS and then cen-
trifuged again as described before. Cell pellet was resuspended in lysis
buffer containing 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1 mM EDTA,
1% w/v Triton X-100 supplemented with 1mM protease inhibitor
cocktail (Sigma-Aldrich), 1 mM DTT, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM NaF and 1mM Na3VO4 for 30min at 4 °C. After
centrifugation at 13,000 rpm for 20min at 4 °C, the supernatant was
collected as a whole cell lysate. The protein concentration was de-
termined by using Bio-Rad protein assay reagent (Bio-Rad, Hercules,
CA, USA).
2.7. Antibodies and Western blotting analysis
For Western blotting analyses, whole cell lysates were prepared and
30 μg of proteins were resolved on 12% SDS–PAGE, transferred onto
nitrocellulose membranes (Schleicher & Schuell Bioscience, Keene, NH,
USA) and incubated with antibodies for p53 1:1000 (#sc-126, Santa
Cruz Biotechnology, Dallas, TX, USA), APE1 1:1000 (#NB-100116,
Thermo Fisher Scientific, Waltham, MA, USA), p21 1:1000 (#2947, Cell
Signaling Technology, Danvers, MA, USA) and actin 1:2000 (#A2066,
Sigma-Aldrich). The corresponding secondary antibodies labelled with
IR-Dye (goat anti-rabbit IgG IRDye 680 and goat anti-mouse IgG IRDye
800, LI-COR Biosciences, Lincoln, NE, USA) were used (1:10,000). Blots
were developed by using the NIR Fluorescence technology (LI-COR
Biosciences). Images were acquired and quantified by using an Odyssey
CLx Infrared Imaging System (LI-COR Biosciences).
2.8. Metabolic activity
Metabolic activity of HCT-116 cell lines was measured through the
MTS CellTiter 96 AQueous One Solution Cell Proliferation Assay and
through RealTime-Glo™MT Cell Viability Assay (Promega) according to
the manufacturer's instructions. In details, 5000 cells were plated on
transparent or black 96-well plates, as needed, and the day after, cells
were treated with the indicated drugs for 48 h. Metabolic activity of
CH12 F3 cell lines was measured with CellTiter 96® Aqueous One
Solution Cell Proliferation Assay (Promega) according to the manu-
facturer's instructions. In details, 10,000 cells were plated on black 96-
well plates and the day after cells were treated with increasing amounts
of Compound #3 or APX2009 at the indicated concentrations for 48 h.
Metabolic activity of patient-derived tumor organoids was measured
through the RealTime-Glo™ MT Cell Viability Assay (Promega) ac-
cording to the manufacturer's instructions. In this case, 3000 cells de-
rived from tumor organoids were plated together with Matrigel on
black 96-well plates and incubated for three days for allowing the
generation of the organoids. Tumor organoids were treated with in-
creasing amounts of Compound #3 for 48 h. For metabolic assay, Y-
27632 was removed from the culture medium.
2.9. AP sites measurements
For the AP sites measurements, 200,000 HCT-116 cells were plated
on 6-well plates and, the following day, cells were treated with
Compound #3. After 48 h, genomic DNA was extracted from the col-
lected cells using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany),
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and concentration and purity were determined by NanoDrop
Microvolume Spectrophotometer (Thermo Fisher Scientific). Samples of
100 μg/ml of genomic DNA were analyzed to quantify abasic sites in
DNA using the DNA Damage Quantification Kit -AP Site Counting-
(Dojindo Molecular Technologies, Kumamoto, Japan) according to the
manufacturer’s instructions.
2.10. Comet assay analysis
The comet assay was performed as previously described [59]. Spe-
cifically, 25,000 cells were plated on 24-well plates and the day after
cells were treated with 0.5 μM Compound #3. After 48 h, cells were
collected and mixed with low melting point agarose at 37 °C, and the
mixture was applied to a agarose pre-coated glass coverslip to form a
thin layer. Cold lysis buffer was added to lyse cells at 4 °C. After 1 h, the
glass coverslip was moved into alkaline electrophoresis buffer for
30min to unwind DNA. Electrophoresis was carried out at 25 V and
300mA for 30min. The glass coverslip was washed with neutralizing
buffer for three times and stained by Sybr Gold 1X (Thermo Fisher
Scientific) for 30min in dark. Comets were recorded by laser scanning
confocal microscope (LEICA TCS SP2, Leica Microsystems, Wetzlar,
Germany). The tail moment was analyzed for 100 cells at random by
OpenComet software.
2.11. Quantitative real-time reverse transcriptase-PCR
For RNA extraction, 200,000 HCT-116 cells were plated on 6-well
plates and, the following day, were treated with Compound #3 or
APX2009. After 48 h, total RNA was extracted from the collected cells
using the NUCLEOSPIN RNA II (MACHEREY-NAGEL GmbH & Co.,
Duren, Germany). The quality of the RNA samples was tested on an
agarose gel. Then, single-strand cDNA was obtained from 1 μg of pur-
ified RNA using SensiFAST cDNA Synthesis Kit (Bioline Meridian
Bioscience, Cincinnati, OH, USA). qRT-PCR was performed using
SensiFAST SYBR No-ROX Kit (Bioline Meridian Bioscience) and a
CFX96 Real-Time System (Bio-Rad). Each sample analysis was per-
formed in triplicate. Samples without template and without reverse
transcriptase were used as negative control,. The cycling parameters
contemplate a first denaturation at 95 °C for 10 s and then 40-cycles of
annealing/extension at 60 °C for 30 s. In order to verify the specificity of
the amplification, a melting-curve analysis was performed, immediately
after the amplification protocol. Relative gene expression was calcu-
lated with the 2−ΔΔCt method. The sequences of the primers used are
the following: APEX1 For 5’-CCTGGACTCTCTCATCAATACTGG-3’,
APEX1 Rev 5’- AGTCAAATTCAGCCACAATCACC-3’, BIRC5 For 5ʹ-
ACCGCATCTCTACATTCAAG-3ʹ, BIRC5 Rev 5ʹ-CAAGTCTGGCTCGTT
CTC-3ʹ, DNA polδ For 5’-GCTCCGCTCCTACACGCTCAA-3’, DNA polδ
Rev 5’-GTCTGGTCGTTCCCATTCTGC-3’ and Actin For 5ʹ-CGCCGCCAG
CTCACCATG-3ʹ, Actin Rev 5ʹ-CACGATGGAGGGGAAGACGG-3ʹ.
2.12. Caspases activity assay
The activities of caspases 3/7 were examined via a fluorescence-
based assay using Apo-ONE® Homogeneous Caspase-3/7 Assay
(Promega) according to the manufacturer's instructions. In details, 5000
cells were plated on white 96-well plates and the day after cells were
treated with increasing amounts of Compound #3 or APX2009 for 48 h.
2.13. Cell mito stress test
Analyses of the mitochondrial function of HCT-116 cells were per-
formed by using XFe Extracellular Flux Analyzer (Seahorse, Agilent
Technologies, Santa Clara, CA, USA) as previously described [60]. In
details, 5000 cells were seeded and cultured in XF Cell Culture Micro-
plates (Agilent Technologies). Before the measurements, the culture
medium was removed from each well and replaced by 500 μl of
Seahorse XF Base Medium (Agilent Technologies), pre-warmed at 37 °C
and supplemented with 10mM glucose (Sigma-Aldrich), 1 mM pyr-
uvate (EuroClone), 2 mM glutamine (Sigma-Aldrich), at pH 7.4. Cells
were incubated in a CO2-free incubator at 37 °C for 1 h and OCR
(oxygen consumption rate) was detected under basal conditions. The
following compounds were prepared at appropriate concentrations for
each injection port to reach the final concentration of 0.5 μM oligo-
mycin A, 0.5 μM FCCP, 1 μM rotenone and 1 μM antimycin A (Sigma-
Aldrich). Volumes of respectively 56, 62, 69 and 73 μl of compounds
were added to each injection port. Then, after a 3-min pause, 3 response
measurements were taken between each addition. OCR values were
normalized to the protein content (μg) of each well obtained by the
Bradford method.
2.14. Immunofluorescence
Patient-derived tumor organoids were grown on a slide and fixed in
4% paraformaldehyde for 20min at 37 °C, then washed with PBS 1X,
treated with 0.1 M glycine in PBS 1X for 10min and permeabilized with
0.5% Triton X-100 in PBS 1X for 5min. After washing with PBS 1X and
blocking for 1 h with 1% BSA, 10% FBS, 0.5% Triton X-100 in Washing
Buffer (10mM Tris HCl pH7.4, 150mM NaCl and 0.01% Tween 20)
organoids were incubated with primary antibodies diluted in blocking
solution o/n at 4 °C. After several washes in PBS 1X, organoids were
incubated with labeled secondary antibodies for 2 h at RT. F-actin was
stained with 0.165 μM Alexa Fluor™ 594 Phalloidin (Thermo Fisher
Scientific) for 20min at RT. For nuclear staining, organoids were in-
cubated with 14.3 mM DAPI (Thermo Fisher Scientific) for 5min at RT.
Organoids were washed and mounted with Mowiol mounting medium.
The following antibodies were used: anti-Ki67 1:200 (#AB92742,
Abcam), anti-OLFM4 1:200 (#14369S, Cell Signaling Technology),
anti-E-Cadherin 1:50 (#610404, BD Biosciences, San Jose, CA, USA)
and anti-Lysozyme 1:200 (#A009902-2, Agilent Technologies). For
detection, Alexa Fluor-488 (#711-546-152 and #715-546-150 Jackson
ImmunoResearch, Ely, UK) antibodies were used. Fluorescent images
were collected using a laser scanning confocal microscope (LEICA TCS
SP8, Leica Microsystems). Brightfield images were collected using a
microscope (LEICA MC170 HD, Leica Microsystems).
2.15. Library preparation and next-generation sequencing
Genomic DNA from tumor organoid was extracted using the
QIAamp DNA Mini Kit (Qiagen) and quantified by using the Quant-iT™
PicoGreen™ dsDNA Assay Kit (LifeTechnologies). Briefly, barcoded li-
braries were generated from 50 ng of DNA per sample (N=3) using the
Ion AmpliSeq Library Kit Plus (Thermo Fisher Scientific) and two pre-
mixed pools of 952 primer pairs (Thermo Fisher Scientific), according
to manufacturer’s instructions. Clonal amplification of libraries was
performed by emulsion PCR on an Ion Chef Instrument. The prepared
libraries were then sequenced on an Ion S5 GeneStudio Sequencer using
a Ion 530 Chip and the Ion 510/520/530 kit–Chef (all Thermo Fisher
Scientific).
2.16. Data analysis and variant prioritization
We analyzed data using Variant Caller v5.10 (Thermo Fisher
Scientific). Variant caller format files were annotated with Ion Reporter
5.10 (Thermo Fisher Scientific) and wANNOVAR. Somatic variants
were called when a position was covered at least 100× . We set the
clinical sensitivity of point mutations and indels at 5%. Variant prior-
itization for TP53 was based on population frequency, quality values
and functional consequences. Synonymous variants were excluded.
Variants were filtered based on their frequency ExAC datasets (http://
exac.broadinstitute.org) and on clinical associations (ClinVar database)
(https://www.ncbi.nlm.nih.gov/clinvar).
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2.17. Bioinformatics analysis
Analysis of APEX1 gene expression in colon cancer was performed
through TCGA data retrieval from cbioportal and CMS class information
were accessed from the original Consensus Molecular Stratification of
colon cancer. Differential gene expression analysis was conducted by
Mann Whitney test. APE1 interactors analysis in colon cancer was
performed using the differential gene expression results from TCGA and
normal datasets (GTEX data) for the genes encoding the interacting
partners of APE1 for colon cancer (COAD). Data was obtained via the
GDC data portal hub (https://portal.gdc.cancer.gov/, last accessed July
2018). The RUVSeq package inside the R/Bioconductor environment
was used to eliminate the batch effect coming from the combination of
two data sources [61]. In order to better estimate the differentially
expressed genes between the tumor and the normal corresponding da-
tasets, we obtained “in-silico empirical” negative controls, i.e., the least
significantly DE genes based on a first-pass DE analysis performed prior
to RUVg normalization [61]. Differentially expressed genes (multiple
correction adjustment using the Benjamini-Hochberg method,
p < 0.05; absolute log fold change difference≥1) were used to per-
form enrichment and survival analyses. Enrichment analysis of the DE
genes was performed using the DAVID functional annotation tool based
on GO biological process and cellular component terms [62]. For the
survival analysis, Kaplan-Meier plots were drawn using the RTCGA
Bioconductor package [63], which uses maximally selected rank sta-
tistics (maxstat) to determine the optimal cutpoint for continuous
variables. Division of the samples was done within the 30–70% per-
centile range of gene expression by the optimal cutpoint value. The
Benjamini-Hochberg method was used for p-value correction of Kaplan-
Meier plots.
2.18. Statistical analyses
All reported values are represented as the mean ± SD or
mean ± SEM of at least three biological replicates. Statistical analyses
were performed using the Student’s t-test. P < 0.05 was considered as
statistically significant.
3. Results
3.1. APE1 is overexpressed in colorectal cancer and the inhibition of its
endonuclease activity triggers p53-mediated effects on cell metabolism
APE1 overexpression is correlated with tumor progression of many
cancers, but little information is available on colorectal cancer (CRC)
[23,24,64]. In order to further determine the involvement of APE1 in
CRC, we took advantage of the information available from TCGA data
sets of CRC. By performing differential gene expression (DEG) analysis
on the TCGA COAD RNA-seq V2 data, we compared the expression
profile of the four consensus molecular subtypes (CMS) of CRC versus
normal control samples [PMC4636487]. The DEG was computed by the
non-parametric Mann Whitney test. A significant upregulation of the
APEX1 gene in the four CMS classes was identified compared to the
normal one (Fig. 1A) (p-value= 1.7e-15, 4e-11, 7.2e-14, 3.5e-11, for the
CMS class 1–4, respectively), however there was no significant differ-
ence between the CMS classes analysed. These data demonstrate that
APE1 is generally overexpressed in CRC, supporting the hypothesis that
it could represent a novel target for the treatment of this cancer type.
We analyzed the effects of APE1 inhibition on colon cancer cell lines
using a number of APE1 specific small molecule inhibitors: Compound
#3, which blocks APE1-endonuclease activity thus leading to genome
instability [35]; APX2009, which inhibits APE1-redox function, leading
to cell-cycle arrest and apoptosis in different cancer cell models [38],
and Fiduxosin, SB206553 and Spiclomazine, as inhibitors of the well-
known interaction between APE1 and NPM1, leading to an alteration of
the APE1-endonuclease activity and to apoptosis in different tumor cell
lines [22,44]. A schematic representation of the APE1-inhibitors used in
this study is shown in Fig. 1B.
To determine the p53 contribution in APE1 inhibitors induced ef-
fects, we took advantage of the well-known HCT-116 p53+/+ and HCT-
116 p53−/− isogenic colon cancer cell lines, which are wild-type and
knock-out for p53 gene expression, respectively [65] (Fig. 1C, top left
panel). Experimentally, HCT-116 cells were treated with increasing
concentrations of different APE1 inhibitors for 48 h. The metabolic
activity of viable cells was measured by using the MTS assay, a col-
orimetric assay which measures the reduction of MTS tetrazolium
compound into formazan in mitochondrial metabolically active cells.
The treatment with the APE1-endonuclease inhibitor Compound #3
demonstrated that HCT-116 p53+/+ cell line was significantly more
sensitive, at the doses of 0.25 μM and 0.5 μM, than HCT-116 p53−/−
(Fig. 1C, top in the middle panel and Table 1 for IC50 values). In order
to understand if the inhibition of APE1-redox activity could have some
effects on HCT-116 cell lines, we treated cells with the APX2009
compound. We did not find a significant difference between HCT-116
p53+/+ and HCT-116 p53−/− cell metabolism upon APX2009 treat-
ment, even if a mild effect can be observed (Fig. 1C, top right panel and
Table 1 for IC50 values). Similarly, no significant differences, between
the two cell lines, were found when inhibitors of APE1 and NPM1 in-
teraction were used, with Fiduxosin being the most toxic for both cell
lines (Fig. 1C, bottom panel and Table 1 for IC50 values). These findings
were in agreement with the presence of no significant difference in the
expression levels of both APE1 and NPM1, as measured at the mRNA
and protein levels (Fig. S1A, B and see below). Moreover, to further
confirm the differential effect of Compound #3 and APX2009 on cell
metabolism of HCT-116 p53+/+ and HCT-116 p53−/− cell lines, we
performed a luminescence-based metabolic assay (RealTime-Glo).
Compared to MTS assay, previously used, RealTime-Glo is a more
sensitive assay based on the measurement of the reducing potential of
mitochondrial metabolic active cells, considering the luminescent
signal produced from the reduction of the substrate used by the luci-
ferase, and thus mitochondrial metabolism. RealTime-Glo assay de-
monstrated that HCT-116 p53+/+ cells presented an impairment of
metabolic activity in comparison to HCT-116 p53−/− upon Compound
#3 treatment, especially at the dose of 0.5 μM, confirming the data
previously obtained through MTS assay (Fig. 1D, right panel and
Table 1 for IC50 values). Interestingly, RealTime-Glo assay revealed that
HCT-116 p53−/− cells underwent a major loss of metabolic activity
compared to HCT-116 p53+/+ cells upon APX2009 administration in a
dose-dependent manner, particularly at the doses of 2.5 μM and 5 μM
(Fig. 1D, right panel and Table 1 for IC50 values). These data demon-
strated that the small difference in metabolic activity that we observed
with MTS assay (Fig. 1C, top right panel) was much more apparent
when the more sensitive RealTime-Glo assay was used in place of the
MTS assay. In order to exclude that the toxic effect could be associated
with an alteration of the doubling time of the HCT-116 p53+/+ and
p53−/− cell lines, we calculated it (HCT-116 p53+/+ 38 ± 2.2 h,
HCT-116 p53-/- 35 ± 2.4 h) and no difference was observed. This ex-
cludes an alteration of the proliferation index as the cause of the effects
on cell viability between the two cell lines.
In order to further validate the specificity of Compound #3 and
APX2009 as APE1 inhibitors in the range of doses used in the present
study, we took advantages of CH12 F3+/+/Δ and CH12 F3Δ/Δ/Δ cell
lines [66], a recently developed murine cell model containing two and
zero copies of APEX1 alleles, respectively (Fig. 1E, left panel). Both
CH12 F3 cell lines were treated with increasing concentrations of
Compound #3 or APX2009 for 48 h and then, the cellular metabolism
of viable cells was measured by using a luminescence-based assay
(CellTiter-Glo), which evaluates the amount of total ATP produced by
cells. As shown in Fig. 1E, APE1-endonuclease and -redox inhibitors
specifically affect CH12 F3+/+/Δ but not CH12 F3Δ/Δ/Δ cell line, as
expected, confirming the high specificity of the inhibitors, under the
experimental conditions used (Table 1 for IC50 values). In the case of
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the effects of Fiduxosin, SB206553 and Spiclomazine, their specificity
was previously demonstrated by us [22,44].
In conclusion, data obtained indicate that the sensitivity of HCT-116
cells to Compound #3 and APX2009 treatment was dependent on their
p53 status. Moreover, the inhibition of APE1-NPM1 interaction impairs
cell metabolism independently of p53 status. Interestingly, while the
toxic effect of Compound #3 was dependent on the expression of p53, a
more toxic effect of APX2009 was apparent in p53 knock-out cells.
3.2. Inhibition of APE1-endonuclease activity promotes p53 activation
We then evaluated whether APE1 inhibition could promote p53
(caption on next page)
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activation. We focused only on Compound #3 and APX2009, since the
APE1-NPM1 inhibitors did not display any significant difference in
terms of biological effects exerted on HCT-116 cell lines. p53 activation
is part of DDR triggered by single-strand breaks (SSBs) and double-
strand breaks (DSBs) formation. We determined whether the amount of
AP sites and SSBs could be affected by the treatment with Compound
#3 in HCT-116 cell lines. AP sites measurements (Fig. 2A) and comet
assay analyses (Fig. 2B and C) clearly demonstrated that Compound #3
treatment promoted a significant increase of AP sites and SSBs forma-
tion in both HCT-116 p53+/+ and HCT-116 p53−/− cell lines in-
dependently of the p53 status at both the doses tested (0.5 μM and 3
μM). The non-significant difference in the levels of AP sites and SSBs
between both HCT-116 cell lines is in agreement with the non-differ-
ential expression of APE1 between the two cell lines used (Fig. S1).
In order to get a better understanding of the relationship existing
between p53, its gene target genes and the inhibition of APE1 enzy-
matic activity in HCT-116 cell lines, we analyzed the protein and mRNA
expression levels of p53 and those of some p53-target genes upon
Compound #3 treatment. In details, HCT-116 p53+/+ and HCT-116
p53−/− cells were treated with increasing concentrations of Compound
#3 (0.25 μM and 0.5 μM) and cells were collected and tested 48 h later.
These doses, with limited effects on cell viability, allowed to avoid
epiphenomena due to general toxic effects and allowed comparison to
data obtained with those obtained with the redox-inhibitor (see below).
Upon the administration of Compound #3, we analyzed the protein
levels of APE1, p53, and p21, one of the major downstream targets of
p53 [47], through Western blotting. We observed a significant increase
of p53 and p21 protein levels upon Compound #3 administration in
HCT-116 p53+/+ cells only, indicating a p53 activation possibly due as
a consequence of cell DDR induction (Fig. 2D). Moreover, the inhibition
of APE1-endonuclease activity did not considerably alter neither APE1
nor NPM1 protein levels in both cell lines, exerting only slight effects.
Densitometric analysis of p53, p21, APE1, and NPM1 protein levels,
normalized to actin levels, is shown in Fig. 2E. Moreover, to further
confirm the unaltered levels of APE1 gene expression upon Compound
#3 treatment, we analyzed its mRNA expression. No statistically sig-
nificant changes in APE1 transcript were observed (Fig. S1C), con-
firming that the higher sensitivity of HCT-116 p53+/+ cell line to
Compound #3 is not due to an impairment of APE1 expression. Fur-
thermore, to test a possible impact of the activation of the p53 pathway
on another known p53-target gene, negatively regulated by p53 and
involved in BER [11,57,67–69], we analyzed the mRNA expression
level of DNA Polymerase δ (DNA Polδ). As it is shown in Fig. 2F, the
level of transcripts of DNA Polδ decreased upon Compound #3 treat-
ment in HCT-116 p53+/+ cells only, in line with p53 induction. These
data support the hypothesis that APE1-endonuclease inhibition causes
the functional activation of p53 protein acting both as a transcriptional
activator and repressor of different target genes.
In order to further support that APE1 inhibition may result in p53
activation, a knockdown approach, through specific siRNA targeting
APE1, was used. As shown in Fig. 2G, knock down of APE1 promoted an
increased expression of p53 in HCT-116 p53+/+ cell line, demon-
strating a mutual inverse relationship between APE1 and p53 (Fig. 2G).
Finally, to generalize the stimulatory effect by Compound #3 on p53
expression, we treated two additional tumor cell lines, i.e. AML2 as a
model of acute myeloid leukemia cells [70] and HCC70 cell line, a triple
negative breast cancer cell line [71]. These cell lines harbor a wild-type
form [70] and a missense mutation (p.R248Q) [71] of the TP53 gene,
respectively. TP53 p.R248Q is a gain-of-function mutation that causes
an aberrant overexpression of the p53 protein. AML2 and HCC70 cell
lines showed an increased expression of p53 upon Compound #3
treatment, demonstrating that the activation of p53 upon inhibition of
APE1-endonuclease activity could be a generalized phenomenon across
different cancer cell lines (Fig. 2H and I) and not only colon specific.
Altogether, these data confirm that APE1-endonuclease inhibitor
treatment of different cancer cell lines promotes p53 expression and its
functional induction.
DNA damage activating the p53-p21 pathway may lead to cell
apoptosis through caspase activation [47]. Therefore, we performed a
Fig. 1. APE1 is overexpressed in colorectal cancer and the inhibition of its endonuclease activity triggers p53-mediated effects on cell metabolism.
(A) Gene expression level of APEX1 in the CRC samples of the four CMS classes and normal controls (CMS1MSI Immune n=71; CMS2 Canonical n= 130; CMS3
Metabolic n= 58; CMS4 Mesenchymal n=98; control n= 42). For left to right, the violin plots illustrate the log(FPKM+1) normalized gene expression level in the
CMS 1–4 class CRC and normal control samples, respectively. (B) Schematic representation of different functions of APE1. The specific inhibitors of the different
functions of APE1 are also indicated. (C) Western blot analysis of p53 and APE1 protein levels in HCT116 p53+/+ and p53−/− cell lines. Actin was used as a loading
control. MTS assay on HCT-116 p53+/+ and p53−/− cell lines. Cells were treated with increasing amounts of APE1 inhibitors (Compound #3, APX2009, Fiduxosin,
SB206553 and Spiclomazine) at the indicated concentrations for 48 h. Untreated cells were treated with DMSO. In graph, the percentage of metabolic activity relative
to untreated cells, arbitrary set to 100%, is represented. Values are mean± SD (n≥3). (D) RealTime Glo assay on HCT-116 p53+/+ and p53−/− cell lines. Cells were
treated with increasing amounts of Compound #3 or APX2009 for 48 h. Untreated cells were treated with DMSO. In graph, the percentage of metabolic activity
relative to untreated cells, arbitrary set to 100%, is represented. Values are mean±SD (n= 3). (E) Western blot analysis of APE1 in CH12 F3+/+/Δ and CH12 F3Δ/Δ/Δ
cell lines. Actin was used as a loading control. CellTiter assay on CH12 F3+/+/Δ and CH12 F3Δ/Δ/Δ cell lines. Cells were treated with increasing amounts of Compound
#3 or APX2009 at the indicated concentrations for 48 h. The percentages of viable cells relative to untreated cells, arbitrary set to 100%, are represented in graph.
Values are mean ± SD (n= 3). Data were evaluated statistically by two-tails Student t-test. Resulting p-value is indicated (* p < 0.05, ** p < 0.01, ***
p < 0.005).
Table 1
List of IC50 values obtained from each model used. The analysis was carried out
using the Combenefit 2.021 software allowing to calculate the IC50 values for
each drug tested on the models analyzed. Cell models (cell lines and patient-
derived 3D tumor organoids), types of assays, drugs and time points are re-
ported. n.d. indicates that the goodness of fit value is too low or a standard Hill
equation does not correctly account for the specific agent used. In some cases,
the expected interpolated IC50 value has been reported.
Model used Drug Time
(hours)
IC50 (μM) Assay
CH12F3+/+/Δ Compound #3 48 1.44 CellTiter
CH12F3Δ/Δ/Δ 1.9
HCT-116 p53+/+ 0.58 MTS
HCT-116 p53−/− 0.69
HCT-116 p53+/+ 1.04 RealTime-Glo
HCT-116 p53−/− 1.50
CH12F3+/+/Δ APX2009 6.61 CellTiter
CH12F3Δ/Δ/Δ 9.64
HCT-116 p53+/+ 11.7 MTS
HCT-116 p53−/− 11.6
HCT-116 p53+/+ 10.0 RealTime-Glo
HCT-116 p53−/− 6.39
HCT-116 p53+/+ Fiduxosin 16.1 MTS
HCT-116 p53−/− 15.6
HCT-116 p53+/+ SB206553 n.d. (> 100)
HCT-116 p53−/− n.d. (> 100)
HCT-116 p53+/+ Spiclomazine 30.4
HCT-116 p53−/− 31.2
HCT-116 p53+/+ MMS 8 721
HCT-116 p53−/− 938
HCT-116 p53+/+ Compound #3 40+8 0.373
HCT-116 p53−/− 0.58
tumor organoid P12 Compound #3 48 1.36 RealTime-Glo
tumor organoid P14 2.8
tumor organoid P16 0.71
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Fig. 2. Inhibition of APE1-endonuclease activity promotes p53 activation.
HCT-116 p53+/+ and p53−/− cell lines were treated with Compound #3 (#3) at the indicated concentrations for 48 h. Untreated cells were treated with DMSO (A-F,
L). (A) The amount of abasic (AP) sites was measurement. Values are mean± SD (n= 3). (B) Representative fluorescence confocal microscope images of in vitro
comet assay. Scale bars, 25 μm. (C) Tail moment was analysed for 100 cells at random by OpenComet software. Untreated cells was used as reference and set to 1.
Values are mean± SD. (D) Western blot analysis of p53, p21, APE1 and Nucleophosmin (NPM1) protein levels. Actin was used as a loading control (n=3). (E)
Densitometric analysis of p53, p21, APE1 and NPM1 protein expression. Levels were normalized to actin. Fold change values relative to untreated control cells,
arbitrary set to 100%, are shown. Values are mean± SD (n=3). (F) Expression level of DNA Polimerase δ (DNA Pol δ) was determined by qRT-PCR analysis. DNA
Pol δ levels were normalized to β-actin. Fold change values relative to untreated control cells, arbitrary set to 1, are shown. Values are mean± SD (n=3). (G)
HCT116 p53+/+ cell lines silenced for APE1 expression. Western blot analysis of p53 and APE1 protein levels. Actin was used as a loading control. Fold change
values relative to untreated control cells, arbitrary set to 1, are shown. (H and I) Western blot analysis of p53 protein levels upon Compound #3 (#3) at the indicated
concentrations of AML2 cell lines treated with for 48 h (H) and HCC70 cell lines treated for 24 h (I). Actin was used as a loading control. Fold change values relative
to untreated control cells, arbitrary set to 1, are shown (n=3). (L) Apo-ONE assay was used to quantify relative levels of apoptosis. The activities of caspases 3/7
were examined using a fluorescence-based assay. Untreated control cells were used as reference and set to 100%. Values are mean± SD (n=2). Data were evaluated
statistically by two-tails Student t-test. Resulting p-value is indicated (* p < 0.05, ** p < 0.01).
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caspase activity assay to measure apoptosis induction by Compound #3
treatment (Fig. 2L). After 48 h of treatment with increasing con-
centrations of Compound #3, Apo-ONE assay was used to quantify re-
lative levels of apoptosis. The treatment with APE1 inhibitor induced
the activation of the caspase pathway in both colon cancer cell lines
(Fig. 2L) occurring only at the highest dose (3 μM) of treatment.
However, no differences were apparent between the two cell lines,
confirming that Caspase activation was independent of p53-activation
and was present only at highest dose of treatment with Compound #3.
Data not shown also demonstrated that Compound #3-treatment did
not exert any significant differential effect on cell cycle of the two
isogenic HCT-116 cell lines.
These experiments, coupled with the metabolic assays, indicate that
the inhibition of the APE1-endonuclease activity promoted a p53-in-
duced response involving mitochondria, which may explain the higher
susceptibility of p53+/+ cell metabolism to Compound #3 treatment in
the absence of significant Caspase-3 activation and of differential effects
on cell cycle between the two HCT-116 isogenic cell lines.
3.3. Inhibition of APE1-redox activity does not affect p53 expression
We analyzed whether inhibition of APE1-redox activity could affect
p53 expression. We checked the efficacy of APX2009 treatment on
HCT-116 colon cancer cell lines, through qRT-PCR on the baculoviral
inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as
Survivin, that was already demonstrated to be a target of APE1-redox
function [40]. Treatment with increasing concentrations of APX2009
promoted a decrease in the expression levels of BIRC5 transcript in both
HCT-116 cell lines (Fig. 3A), in line with previously demonstrated data
on different cell lines [40].
To assess whether APE1-redox inhibitor stimulates the p53-
pathway, we performed the same set of experiments, as with Compound
#3, but with APX2009. We used APX2009 at concentrations of 5 μM
and 10 μM, that promoted a reduction in cell viability of less than 40%
similar to the conditions used with Compound #3 treatment. As shown
in Fig. 3B and C, no differences in p53 and in the expression of the p21
target gene were observed upon the administration of the redox in-
hibitor. Moreover, DNA Polδ transcript did not significantly change
following APX2009 administration, in agreement with the lack of any
stimulatory effects by the APE1-redox inhibition on p53 levels
(Fig. 3D). Moreover, the caspase activity assay demonstrated a dose-
dependent activation of the caspase pathway indistinctly in both colon
cancer cell lines (Fig. 3E).
Taken together, these experiments demonstrate that the inhibition
of the APE1-redox activity does not activate a p53-mediated cell re-
sponse and this is in agreement with data on cell metabolism.
3.4. Inhibition of APE1-endonuclease activity impairs mitochondrial
activity in a p53-dependent manner
Data obtained so far, through MTS and RealTime-Glo analyses,
point to a major role of the p53-dependent effect of Compound #3 on
cell viability due to metabolic effects associated with mitochondrial
toxicity. In order to better characterize this aspect, we directly analyzed
mitochondrial activity using the Cell Mito Stress Test [72] upon Com-
pound #3 treatment. Specifically, HCT-116 p53+/+ and HCT-116
p53−/− cell lines were treated with 0.5 μM of Compound #3 for 48 h
and were analysed for mitochondrial respiration. The parameters of
basal oxygen consumption, respiration coupled to ATP production,
spare respiratory capacity and maximal respiration were obtained
through oxygen consumption rate (OCR) profile. As represented in
Fig. 4A, OCR profile indicates that Compound #3 impaired the mi-
tochondrial activity of HCT-116 p53+/+ cells, while the treatment did
not significantly alter the mitochondrial function of HCT-116 p53-/-
cells. In particular, the OCR values were comparable between the two
colon cancer cell lines under basal conditions. Interestingly, Compound
#3 treatment affected the majority of the respiratory parameters in a
p53-dependent manner (Fig. 4B). Among them, the basal and ATP-
coupled respiration was significantly lower in HCT-116 p53+/+ than
the isogenic p53-/- counterpart upon treatment. Moreover, the spare
respiratory capacity and maximal respiration were impaired in HCT-
116 p53+/+ treated cells in comparison to the untreated condition. On
the other hand, we did not observe any difference in mitochondrial
function in p53-null colon cancer cell line upon treatment. The OCR
profiles of HCT-116 p53+/+ and p53-/- cell lines with Compound #3 at
different concentrations (0.25 μM and 1 μM) are shown in Fig. S2,
confirming the obtained results, particularly at the dose of 1 μM.
Overall, the data obtained suggest that the expression of p53 is re-
sponsible for the observed effects on cell metabolism, upon inhibition of
APE1-endonuclease activity, through an involvement of mitochondrial
respiratory function.
3.5. Inhibition of APE1-endonuclease activity sensitizes p53 expressing cell
lines to MMS treatment
Based on the results obtained so far, we analyzed the effect of p53
on cell metabolism in combination with a genotoxic insult, which is
specifically repaired through the enzymatic activity of APE1 and BER
[73]. We used methyl methanesulfonate (MMS), an alkylating agent
generating damages specifically repaired through BER [73]. Experi-
mentally, HCT-116 cells were treated with increasing concentrations of
Compound #3 (0.25 μM and 0.5 μM) for 40 h and in combination with
MMS (range from 200 μM to 600 μM) for additional 8 h (Fig. 5). After a
total of 48 h of treatment, cell metabolism was measured using the MTS
assay (Table 1 for IC50 values). The graphs in Fig. 5A-C clearly shows
that the two isogenic cell lines responded similarly sensitive to MMS.
Interestingly, when Compound #3 was used in combination with MMS,
the sensitivity to the drug treatment increased (Fig. 5A-C); however, the
p53-null colon cancer cells were significantly less sensitive to combi-
nation treatment than the isogenic counterpart (Table 1 for IC50 va-
lues), in particular at the dose of 600 μM of MMS, in agreement with the
stimulatory effect of Compound #3 on p53 expression demonstrated
above.
These results suggest that p53-status is essential for cellular re-
sistance to genotoxic stress upon the inhibition of APE1-endonuclease
activity.
3.6. Inhibition of APE1-endonuclease activity exerts toxic effects on patient-
derived tumor organoids metabolism and is associated with the p53-
mutational status
In order to further validate the possible opportunity of targeting the
APE1-endonuclease activity in CRC and further supporting our data
previously obtained with HCT-116 isogenic cancer cell lines, we per-
formed targeted experiments by using 3D tumor organoids derived from
three different patients affected by colon cancer (P12, P14 and P16).
The molecular and morphological characterization, obtained through
immunofluorescence, is shown in Fig. 6A. Patient-derived tumor orga-
noids were positive for the most common intestinal markers, such as
Ki67 (proliferating cells), OLFM4 (intestinal stem cells), E-Cadherin
(intestinal epithelial cells) and Lysozyme (Paneth cells). Representative
images of the molecular morphology of the patient-derived tumor or-
ganoids are shown in Fig. 6B. To check the p53-functional status of
these model organoids, genomic DNA was isolated from tumor orga-
noids and used as a template for next generation sequencing analysis,
using the Ion Torrent S5 GeneStudio NGS platform. After variant calling
filtration and annotation, we detected a c.586C > T stop-gain muta-
tion (p.R196X) in P14 and a c.524 G > A missense mutation
(p.R175 H) in P16, the latter being a structural aminoacidic substitution
causing a TP53 gain-of-function and wild-type alleles in P12 (Fig. 6C).
All samples did not bear any pathogenic alteration of APEX1 gene se-
quence. The western blotting analysis demonstrated that p53 was
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expressed in P12 and P16 but not in P14, in agreement with sequencing
data (Fig. 6D). No major differences in APE1 protein expression level
were assessed among tumor organoids (Fig. 6E), with only a mild in-
crease in P14 and P16 with respect to P12. We treated the different
tumor organoids with increasing concentrations of Compound #3
(range from 0.5 to 5 μM) and cell metabolism was measured by using
RealTime-Glo assay upon 48 h of treatment. Interestingly, the treatment
with APE1-endonuclease inhibitor impaired the cell metabolism of all
tumor organoids in a dose-dependent manner but to different extents
(Fig. 6F and Table 1 for IC50 values). The reduction of cell metabolism
was observed within a range of 40–65% at the concentration of 5 μM.
Interestingly, we observed a different cytotoxic sensitivity of the three
tumor organoids to Compound #3 that was dependent on their p53
status. In particular, tumor organoids expressing wild-type p53 (P12)
and the R175H gain-of-function mutant (P16) were more sensitive to
APE1 inhibition than the P14 null-mutant, in agreement with the data
obtained with the colon cancer cell lines.
Even though the limited number of sample patients, these results
indicate that the inhibition of APE1-endonuclease activity significantly
hampers the patients-derived tumor organoids metabolism and is as-
sociated with the p53 mutational status, in agreement with data ob-
tained with HCT-116 cell lines.
4. Discussion
Human cells are constantly subjected to potentially damaging
events to the stability of nucleic acid, with tens of thousands of DNA
lesions occurring per day [74]. The intestinal tract is exposed to mul-
tiple insults coming from metabolic activity of the microenvironment
[75] and from the diet [7], that can lead to mutations or deletions in the
DNA of epithelial cells. In the intestinal tract, the involvement of the
direct reversal of DNA damage by O6-methylguanine-DNA methyl-
transferase (MGMT), nucleotide excision repair (NER) and base excision
repair (BER) have been described [7]. Alterations of these repair me-
chanisms are clearly associated with tumor development but also re-
present an emerging ‘Achilles’ heel’ for the development of new
Fig. 3. Inhibition of APE1-redox activity does not affect p53 expression.
HCT-116 p53+/+ and HCT-116 p53−/− cells were treated with APX2009 (APX) at the indicated concentrations for 48 h. Untreated cells were treated with DMSO.
(A) Expression level of BIRC5 was determined by qRT-PCR analysis. BIRC5 levels were normalized to β-actin. Fold change expression values relative to untreated
cells, arbitrary set to 1, are shown. Values are mean±SD (n= 3). (B) Western blot analysis of p53, p21, APE1 and Nucleophosmin (NPM1) protein levels. Actin was
used as a loading control (n= 3). (C) Densitometric analysis of p53, p21, APE1 and NPM1 protein expression. Levels were normalized to actin. Fold change values
relative to untreated control cells, arbitrary set to 100%, are shown. Values are mean±SD (n= 3). (D) Expression level of DNA Polimerase δ (DNA Pol δ) was
determined by qRT-PCR analysis. DNA Pol δ levels were normalized to β-actin. Fold change expression values relative to untreated control cells, arbitrary set to 1, are
shown. Values are mean± SD (n=3). (E) Apo-ONE assay was used to quantify relative levels of apoptosis. The activities of caspases 3/7 were examined using a
fluorescence-based assay. Untreated control cells were used as reference and set to 100%. Values are mean± SD (n= 3). Data were evaluated statistically by two-
tails Student t-test. Resulting p-value is indicated (* p < 0.05, ** p < 0.01).
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anticancer strategies [76]. Indeed, a dysregulation of BER has been
observed in different tumors, such as breast, liver, melanoma, bladder
and colorectal cancer (CRC) [6,77–81]. In the case of CRC, an increased
expression of BER enzymes is associated with a poor prognosis and
contributes to chemoresistance [6]. In particular, higher levels of N-
methylpurine-DNA glycosylase (MPG), 8-oxoguanine-DNA glycosylase
(OGG1), APE1, PARP1, DNA polymerase β (Polβ) and XRCC1 are as-
sociated with adverse outcomes in patients with sporadic CRC [6,81].
Interestingly, the tumor suppressor p53, frequently mutated in the late
stages of CRC [48], is involved in the regulation of DNA glycosylases
(OGG1 and MUTYH) [52,53], APE1 [54,55], Pol β [56] and Pol δ [57]
expression. Generally, upon genotoxic lesions, p53 regulates the ex-
pression of DNA repair genes [68], as in the case of APE1 that is ne-
gatively regulated by p53 through modulation of Sp1 stability [57].
Therefore, impaired p53 results in a loss of transcriptional regulation
thus leading to BER imbalance and genome instability. Moreover, the
DNA repair capacity of BER has been taken into account as a prognostic
factor to 5-Fluorouracil (5-FU) treatment in CRC-affected patients, as
demonstrated by a recent publication showing that a good therapy re-
sponse is correlated with an observed higher activity of BER in non-
malignant adjacent mucosa and a lower BER activity in tumor tissue
[82]. To date, the therapeutic effect of the only APE1-redox inhibitor
has been highlighted in different cancer cell lines. For example,
APX3330 inhibits cell growth in tumor endothelium/endothelial pro-
genitor cells [83], leukemia [31], pancreatic [84,85], breast [86], he-
patocellular [87], prostate cancer cells [88] and colon [23]. It should be
noted that APE1-redox inhibitor APX3330 recently completed a cancer
Phase I clinical trial (https://clinicaltrials.gov/ct2/show/
NCT03375086) [42,43]. Thus, discovering new drugs able to inhibit
the activity of APE1 in a CRC context could be a promising field in the
precision medicine. However, no studies targeting the APE1-en-
donuclease activity and its effect on p53 activation have been pub-
lished. Here, we demonstrated the anticancer effects of different APE1
inhibitors in colon cancer cells and their relationship with p53 activa-
tion. By using different technical approaches, we observed a p53-de-
pendent metabolic impairment, impacting on mitochondrial respiratory
mechanisms, of HCT-116 cell lines upon treatment with APE1-en-
donuclease inhibitor, proving the effectiveness of the treatments also in
a CRC context. It is noteworthy to mention that the APX2009 redox
inhibitor resulted more toxic to p53 knock-out cells than wild-type
counterpart. This observation will need additional studies to under-
stand the molecular basis for this effect.
In our case, the increased p53 level, following the DNA damage (AP
site accumulation and SSBs generation) caused by APE1-endonuclease
inhibition, was not associated with any changes in APE1 mRNA and
protein levels, in contrast to what was previously demonstrated in other
papers, in which p53 was demonstrated to negatively regulate APE1
gene expression [55]. Moreover, we did not observe any p53 stimula-
tion caused by APX2009 treatment, therefore suggesting the possibility
to target different APE1 activities by acting through different response
mechanisms either involving the DNA-repair or the redox-functions. We
also observed that the inhibition of APE1-endonuclease activity pro-
motes p53 activation not only in colon cancer cells, but also in breast
and leukemia cancer cell lines, suggesting that the APE1 inactivation
and the consequent accumulation of DNA damage converge toward p53
activation. Thus, the use of APE1-endonuclease inhibitors could be
Fig. 4. Inhibition of APE1-endonuclease activity impairs mitochondrial activity in a p53-dependent manner.
(A and B) HCT-116 p53+/+ and p53−/− cells were seeded in a Seahorse XF-24 analyzer and treated with 0.5 μM of Compund#3 for 48 h. Untreated cells were
treated with DMSO. (A) Real-time oxygen consumption rate (OCR) was determined during sequential treatments with oligomycin (ATP-synthase inhibitor), FCCP
(uncoupler of oxidative phosphorylation), rotenone (complex I inhibitor) and antimycin-A (complex III inhibitor). (B) The rates of basal respiration, ATP-coupled
respiration, spare respiratory capacity and maximal respiration were quantified by normalization of OCR level to total protein content. Data represent means ± SEM
(n=3). Data were evaluated statistically by two-tails Student t-test. Resulting p-value is indicated (* p < 0.05).
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particularly relevant considering the p53-functional status of the spe-
cific tumor.
Another relevant finding regards the effect of APE1-endonuclease
inhibitor on CRC patient-derived tumor organoids. Our study demon-
strates that Compound #3 impairs the viability of CRC patient-derived
organoids in a dose-dependent manner and in a p53-dependent muta-
tional status, which is in agreement with our findings obtained from
cancer cell lines.
To our knowledge, the observation that the APE1-endonuclease
inhibitor effects are possibly related to the p53 role on mitochondrial
metabolism is extremely important. Besides cell cycle arrest, apoptosis
and senescence, p53 plays an important function also in mitochondrial
respiration [89]. As a regulator, p53 induces the expression of cyto-
chrome c oxidase 2 (SCO2), ferredoxin reductase (FDXR) and glutamine
2 (GLS2), thus modulating oxidative phosphorylation and tricarboxylic
acid (TCA) cycle [89,90]. Moreover, the involvement of BER in mi-
tochondrial homeostasis has been extensively demonstrated. Indeed,
p53 regulates mitochondrial BER in removing oxidized bases of the
mtDNA generated by reactive oxygen species (ROS) metabolism [91].
Notably, Compound #3 sensitizes p53-expressing colon cancer cells to
genotoxic treatment, such as MMS. Due to the relevance of APE1 in-
hibition on mitochondrial functionality in a p53-dependent manner, we
performed additional bioinformatics analyses that clearly pointed to a
major role of mitochondrial toxicity correlated with APE1 functional
dysregulation in tumors. It is also possible that the effect of Compound
#3 could be also exerted through inhibition of mitochondrial APE1
[92–94], whose role is still debated. An important confirmation of the
mitochondrial role of APE1 linking to p53 activation is also supported
by our recent findings (Ayyildiz D. et al., submitted). In fact, when
characterizing the APE1 protein-protein interactome (PPI) in different
cancers cells, we found that the differential expression status of APE1
PPI was clearly associated with bad prognosis signatures in cancers
(Ayyildiz D. et al., submitted). TCGA analyses demonstrated that in
CRC, 79% (n=287) of APE1 PPI resulted in upregulation, while 21%
(n= 77) of the genes altered in expression were downregulated
(Fig. 7A). Based on the relationship existing between these differen-
tially expressed interactors, by focusing on their subcellular localiza-
tions through functional enrichment analysis based on GO CC terms, we
observed that 24% (n=70) of the upregulated and 12% (n=9) of the
downregulated interactors were mitochondria-associated proteins
(Fig. 7A). The subcellular localizations and enrichment results of these
differentially-regulated physical-interactors of APE1 are shown in
Fig. 7B. The enrichment analysis highlighted pathways that can im-
prove our understanding of the importance of APE1 for mitochondrial
activity. Among them, mitochondrial RNA processing, fatty-acid oxi-
dation, respiratory complex III and apoptosis represented the most
important ones (Fig. 7B). All these processes are essential for cancer
metabolism [95,96], as in the case of the mitochondrial respiratory
complex III, that plays a role in CRC progression [97]. Interestingly,
some of these interactors were found to be significantly regulated in our
previously published microarray data [98], such as AK2, CKB, CLIC4,
DNAJA1, DUT, HSPA1A, IDH1, KYNU, MTCH2, SHMT2, SIRT1 and
YWHAH (marked in red circle in Fig. 7B). SIRT1, which regulates BER
modulating the acetylation status of APE1 [73], has been found upre-
gulated in various cancer cell lines, including HCT-116 cell line [99].
The survival signature of the 79 interactors were also confirmed by
Kaplan-Meier analysis in TCGA colon cancer dataset (COAD) and
BCAP31, CDKN2A, DUT, NIF3L1 and SHMT2 were associated to poor
prognosis (marked with red star in Fig. 7B). Together, this evidences
support our findings, namely the mitochondrial impairment related to
p53 upon Compound #3 treatment. The experimental data we provide,
together with these bioinformatics analyses, support the hypothesis to
target mitochondrial function in cancer cells through APE1-en-
donuclease inhibitors. More tailored studies are needed along these
lines.
In conclusion, our data highlights novel relevant aspects regarding
developing new strategies for targeting BER, and especially APE1
functions, in CRC. Therefore, the opportunity to use APE1-en-
donuclease inhibitors, such as Compound #3, in cancer therapy should
not be underestimated. Finally, greater treatment efficacy and reduced
drug resistance onset mechanisms have been demonstrated when dif-
ferent anti-cancer drugs are combined together [100], thus the possi-
bility of studying the effects of the different combination of APE1 in-
hibitors with well-known chemotherapeutic agents may open new
perspectives in cancer biology research.
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